GRAIL to Present New Data on Multi-Cancer Early Detection Test
Presentations will feature results from the NHS-Galleri and PATHFINDER 2 studies involving more than 174,000 participants.
Category: Molecular Diagnostics
Molecular Diagnostics
Latest
Molecular Diagnostics
Latest
FDA Grants Breakthrough Designation to Breast Cancer Risk Assessment Test
The FDA has granted Breakthrough Device designation to PreludeDx’s AidaBREAST assay, which uses multi-omic data and AI to assess recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
Molecular Diagnostics
Latest
Watchmaker Genomics Launches Molecular Kits Aimed at Faster Point-of-Care Results
Watchmaker Genomics has launched new RT-qPCR and qPCR kits, enabling assay developers to create rapid, robust point-of-care and field-deployable molecular diagnostic tests, with results in under 10 minutes.
Genomics Study Identifies 100 Genetic Causes of Vision Loss
A national study in Abu Dhabi used data from 500,000 citizens to improve early detection and prevention of inherited eye diseases.
Read More
Ultima Genomics Presents New Data for Cancer Detection Technology at AACR 2026
Ultima Genomics presented data at AACR 2026 showing its ppmSeq technology detected circulating tumor DNA at low single-digit parts-per-million in a TRACERx pilot of 50 plasma samples.
Read More
FDA Grants Breakthrough Status to Liquid Biopsy for Liver Cancer Monitoring
TCM Biotech has received FDA Breakthrough Device Designation for CatCHimera, a liquid biopsy platform for monitoring minimal residual disease in hepatocellular carcinoma using HBV–host genome integration biomarkers.
Read More
Blood Test Shows Promise for Detecting Glioblastoma Using microRNA Signatures
A study identified microRNA patterns in blood plasma that could support noninvasive diagnosis and monitoring of the most aggressive form of brain cancer.
Read More
Optical Genome Mapping Catches Missed Genetic Variants in Nearly 20% of Acute Leukemia Cases
Optical genome mapping detected clinically significant genetic variants missed by standard tests in nearly 20% of acute leukemia cases, according to a 200-patient study.
Read More
Seegene Introduces New Data Platform and Automated PCR System
Seegene unveiled its STAgora real-time data analytics platform and an updated CURECA automated PCR system at ESCMID Global 2026, aiming to enhance infectious disease monitoring through integrated laboratory workflows and aggregated test data.
Read More
Genome Detective Unveils Automated Pathogen Genomics Platform
The cloud-based system aims to address the bottleneck of translating raw genomic data into actionable information for clinical laboratories.
Read More
QuidelOrtho Completes Acquisition of LEX Diagnostics and Molecular Testing Platform
The $100 million deal brings an ultra-fast system for respiratory viruses to QuidelOrtho’s point-of-care portfolio.
Read More
Biocartis Earns European Certification for Colorectal Cancer Companion Diagnostic Test
The Idylla CDx MSI Test detects microsatellite instability in colorectal cancer tissue in under three hours, supporting therapy selection for eligible patients.
Read More
CellCarta Secures Exclusive Global Rights to Deploy Aspyre Lung Assay in Lung Cancer Clinical Trials
CellCarta has secured exclusive global rights to deploy Biofidelity’s Aspyre Lung assay in lung cancer clinical trials, streamlining genomic testing for trial sponsors and reducing reliance on multiple vendors.
Read More
Seed Funding to Advance Biopsy Catchment Technology and Liquid Specimen Biorepository
A $4 million financing round will support development of a liquid specimen biorepository and expand biopsy catchment pilot programs at medical institutions across the US.
Read More
GeneCentric Data Suggest Fragmentomics Could Expand Liquid Biopsy Beyond Mutation Testing
Presentations at AACR 2026 will showcase fragmentomics-based technology for detecting therapeutic markers and providing prognostic insight.
Read More
NeoGenomics to Spotlight AI-Driven Genomic–Clinical Data Integration at AACR 2026
Presentations at the upcoming annual meeting will focus on AI-based analysis, biomarker prevalence, and therapy development.
Read More
FDA Issues Draft Guidance for Gene Therapy Genome Editing Safety
The recommendations focus on using next-generation sequencing to evaluate off-target editing risks and chromosomal integrity.
Read More
New Research on Automated Myeloid Testing and Molecular Residual Disease to be Presented at AACR 2026
Biodesix will present seven abstracts—including two oral sessions—at AACR 2026, highlighting advances in automated myeloid testing, liquid biopsy, and NGS-based cancer monitoring platforms.
Read More
- 1
- ...
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- ...
- 102